Abstract：The incidence of prostate cancer has been increasing and multiparametric magnetic resonance imaging is emerging as a useful clinical technique for detecting and diagnosing prostate cancer. Quantitative analysis of dynamic contrast-enhanced MRI (DCE-MRI) has greatly improved the diagnostic accuracy of prostate cancers by measuring tissue perfusion and vascular permeability. This review focused on the basic principles, reproducibility and clinical applications of quantitative DCE-MRI analysis in diagnosis of prostate cancer.
马露,,叶慧义,王海屹. 动态增强MRI定量分析在前列腺癌诊断中的应用[J]. 微创泌尿外科杂志, 2018, 7(s1): 30-.
Ma Lu, Ye Huiyi, Wang Haiyi. Applications of quantitative dynamic contrast-enhanced MRI analysis in prostate cancer. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2018, 7(s1): 30-.
[1]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin, 2015,65(1):5-29.
[2]Nicholson B, Schaefer G, Theodorescu D. Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer Metastasis Rev, 2001,20(3-4):297-319.
[3] Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol, 1993,24(2):220-226.
[4]Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer, 1995,75(10):2545-2551.
[5]李春媚,陈敏,李飒英,等.前列腺癌MR动态增强扫描定量分析及其应用.中华放射学杂志,2011,45(5):508-510.
[6]Wang H, Su Z, Ye H, et al. Reproducibility of dynamic contrast-enhanced MRI in Renal Cell Carcinoma: A prospective analysis on intra-and interobserver and scan-rescan performance of pharmacokinetic parameters. Medicine, 2015,94(37):e1529.
[7]Beresford MJ, Padhani AR, Taylor NJ, et al. Inter-and Intraobserver variability in the evaluation of dynamic breast cacer MRI. J Magn Reson Imaging, 2006,24(6):1316-1325.
[8]Jackson A, Jayson GC, Li KL, et al. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol, 2003,76(903):153-162.
[9]Barnes SL, Whisenant JG, Loveless ME, et al. Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer. Magn Reson Med, 2013;69(6):1721-1734
[10]Lowry M, Zelhof B, Liney GP, et al. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue. Inves Radiol, 2009,44(9):577-584.
[11]Ng CS, Wei W, Bankson JA, et al. Dependence of DCE-MRI biomarker values on analysis algorithm. PloS one, 2015,10(7):e0130168.
[12]Yang C, Karczmar GS, Medved M, et al. Reproducibility assessment of a multiple reference tissue method for quantitative DCE-MRI analysis. Magn Reson Med, 2009,61(4):851-859.
[13]Huang W, Chen Y, Fedorov A, et al. The impact of arterial input function determination variations on prostate dynamic contrast-enhanced Magnetic Resonance Imaging pharmacokinetic modeling: A multicenter data analysis challenge. Tomography, 2016,2(1):56-66.
[14]Cheng HL. Investigation and optimization of parameter accuracy in dynamic contrast-enhanced MRI. J Magn Reson Imaging, 2008,28(3):736-743.
[15]Heye T, Davenport MS, Horvath JJ, et al. Reproducibility of dynamic contrast-enhanced MR imaging. Part I. Perfusion characteristics in the female pelvis by using multiple computer-aided diagnosis perfusion analysis solutions. Radiology, 2013,266(3):801-811.
[16]Dale BM, Jesberger JA, Lewin JS, et al. Determining and optimizing the precision of quantitative measurements of perfusion from dynamic contrast enhanced MRI. J Magn Reson Imaging, 2003,18(5):575-584.
[17]Durmus T, Vollnberg B, Schwenke C, et al. Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA. Rofo, 2013,185(9):862-868.
[18]Ocak I, Bernardo M, Metzger G, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3-T: a study of pharmacokinetic parameters. AJR Am J Roentgenol, 2007,189(4):849.
[19]何为,刘毅,刘剑羽,等.3.0T MR动态增强扫描定量分析诊断前列腺癌的价值.中华放射学杂志. 2014, 48(3):215-218.
[20]Fütterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology, 2006,241(2):449-458.
[21]Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol, 2000,55(2):99-109.
[22]Schlemmer HP, Merkle J, Grobholz R, et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens. Eur Radiol, 2004,14(2):309-317.
[23]Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology, 2010, 257(3): 715-723
[24]Hoeks CM, Hambrock T, Yakar D, et al. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology, 2013,266(1):207-217.
[25]Elbuluk O, Muradyan N, Shih J, et al. Differentiating transition zone cancers from benign prostatic hyperplasia by quantitative multiparametric Magnetic Resonance Imaging. J Comput Assist Tomogr, 2016,40(2):218-224.
[26]王世威,喻迎星,潘智勇,等.3.0T定量动态对比增强MRI对中央区前列腺癌的应用价值研究.医学影像学杂志,2014,24(5):824-827.
[27]Jackson AS, Reinsberg SA, Sohaib SA, et al. Dynamic contrast-enhanced MRI for prostate cancer localization. Br J Radiol, 2009,82(974):148-156.
[28]Verma S, Turkbey B, Muradyan N, et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol, 2012,198(6):1277-1288.
[29]朱海滨,江柳,杨学东,等.MR动态增强定量参数Ktrans值对前列腺外周带T2WI递信号病灶的鉴别诊断价值.实用放射学杂志,2012,28(12):1838-1841.
[30]Langer DL, van der Kwast TH, Evans AJ, et, al. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging, 2009,30(2):327-334.
[31]Donati OF, Jung SI, Vargas HA, et al. Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? Radiology, 2013,268(2):440-450.
[32]Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol, 2003,169(2):517-523.
[33]Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys, 2003,57(4):915-928.
[34]Yakar D, Hambrock T, Huisman H, et al. Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy. Invest Radiol, 2010,45(3):121-125.
[35]Akin O, Gultekin DH, Vargas HA, et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol, 2011,21(9):1970-1978.
[36]Panebianco V, Sciarra A, Lisi D, et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F] choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol, 2012,81(4):700-708.
